Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term impact (< 12 months) unintended adverse events ‐ not reported · children aged 5 years and under
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults without cardiovascular disease
1 finding from 1 review
Adverse events · adults with established cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults without cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people prescribed medication for primary prevention of cardiovascular disease
1 finding from 1 review
Short‐term impact (< 12 months) unintended adverse events · children aged 5 years and under
1 finding from 1 review
Adverse events · adults with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (12 (12, 26)) · people with congenital heart disease.
1 finding from 1 review
Adverse events · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (Vitamin B6 (pyridoxine;… showed no clear difference in adverse events compared with placebo or standard care (high certainty).
1 finding from 1 review
Adverse events · adults with established cardiovascular disease
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in adverse events compared with non‐active comparators (low certainty).
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · adults (age 18 years or over) with myocardial infarction, stable angina, following coronary artery bypass graft surgery or percutaneous…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) (high certainty).
1 finding from 1 review
Serious adverse events · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) plus placebo (high certainty).
1 finding from 1 review
Serious adverse events ( · adult patients with an implantable cardioverter defibrillator
Exercise showed no clear difference in serious adverse events ( compared with no exercise at the end of the intervention (low certainty).
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review